Grace Therapeutics, Inc.
Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.
Raised
$10M
Investors
9
Min Invest
$1
Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.
What this filing shows
·Every sentence is a value as filed on SEC Form D
Grace Therapeutics, Inc. is a Delaware corporation that filed a Form D with the SEC on August 11, 2026 in the Pharmaceuticals industry group. The offering claims Rule 506(b) and covers equity. Grace Therapeutics, Inc. reported $9,999,998 sold from 9 investors of a $9,999,998 total offering as of the Form D filed August 11, 2026. The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The minimum investment accepted from an outside investor is $1. The Form D names Craig-Hallum Capital Group (CRD 000121395), associated with None as the recipient of sales compensation. The issuer's address of record is 103 Carnegie Center, Suite 300, Princeton, NJ 08540.
EDGAR Filing Data
Form D — Primary Source
View on SEC.govFilings on Record
Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.
In the Terminal
Filing events
2
latest Aug 11, 2026
Critical / warning
0 / 0
0 watch · 2 info
Statements extracted
0
none on file
NAV prints
0
none on file
Offering chains
4
closed, lapsed
Latest event New filer · Aug 11, 2026
SEC.govInvestor
- 2 filing events with values and deltas, latest 2026-08-11, and alerts on the next one
- 4 offering timelines: velocity, share raised, first-sale lag, stalled flags
Pro
- This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
- The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV
Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…
Related Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
Item 3 changed on the Form D filed 2026-08-11: 0 related persons added and 1 removed against the filing of 2025-02-25; 8 now listed. The names are in the Terminal feed.
Prashant Kohli
Executive Officer, Director · Princeton, NJ
Chief Executive Officer
Vimal Kavuru
Director · Princeton, NJ
Robert J. DelAversano
Executive Officer · Princeton, NJ
Vice President, Finance, Principal Financial Officer and Principal Accounting Officer
A. Brian Davis
Director · Princeton, NJ
S. George Kottayil
Director · Princeton, NJ
Edward Neugeboren
Director · Princeton, NJ
Dr. R. Loch Macdonald
Executive Officer · Princeton, NJ
Chief Medical Officer
Amresh Kumar
Executive Officer · Princeton, NJ
VP of Program Management
Placement Agents and Sales Compensation (Form D)
Who the issuer reported paying to sell the securities (Form D Item 12), with the FINRA registration number the filer gave. Source: SEC.gov.
Craig-Hallum Capital GroupCRD 000121395 on BrokerCheck
Associated broker-dealer: None · Minneapolis, MN and outside the United States
Questions About Grace Therapeutics, Inc.
Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.
What is Grace Therapeutics, Inc.?
Grace Therapeutics, Inc. is a Delaware corporation that filed a Form D with the SEC on August 11, 2026 in the Pharmaceuticals industry group. The filing claims Rule 506(b) for an offering of equity.
Is Grace Therapeutics, Inc. legit?
AltStreet does not rate legitimacy; it reports the public record. Grace Therapeutics, Inc. filed a Form D with the SEC on August 11, 2026 claiming Rule 506(b). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $9,999,998 sold to 9 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.
Is Grace Therapeutics, Inc. registered with or approved by the SEC?
No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Grace Therapeutics, Inc. claimed Rule 506(b) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.
How much has Grace Therapeutics, Inc. raised?
Grace Therapeutics, Inc. reported $9,999,998 sold from 9 investors of a $9,999,998 total offering as of the Form D filed August 11, 2026.
Who can invest in Grace Therapeutics, Inc.?
The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The minimum investment accepted from an outside investor is $1.
What is the minimum investment in Grace Therapeutics, Inc.?
The Form D lists $1 as the minimum investment accepted from any outside investor as of August 11, 2026. Issuers can waive their own minimums, and the figure does not include fees.
Who is selling Grace Therapeutics, Inc. and how are they paid?
The Form D names Craig-Hallum Capital Group (CRD 000121395), associated with None as the recipient of sales compensation.
Who is behind Grace Therapeutics, Inc.?
The Form D lists 8 related persons: Prashant Kohli, executive officer, director (Chief Executive Officer); Vimal Kavuru, director; Robert J. DelAversano, executive officer (Vice President, Finance, Principal Financial Officer and Principal Accounting Officer); A. Brian Davis, director; S. George Kottayil, director; Edward Neugeboren, director; Dr. R. Loch Macdonald, executive officer (Chief Medical Officer); Amresh Kumar, executive officer (VP of Program Management). Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.
Where is Grace Therapeutics, Inc. located?
The issuer's address on its SEC filings is 103 Carnegie Center, Suite 300, Princeton, NJ 08540. Its phone number of record is 609-322-1602. It is organized under the laws of Delaware.
How long is the Grace Therapeutics, Inc. offering open?
The issuer indicated that the offering is not intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open, and no amendment is on record yet.
What is Grace Therapeutics, Inc.'s revenue?
The Form D reports a revenue range of No Revenues.

Is this your company or fund?
Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.
Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.
